Ignite Creation Date:
2024-06-16 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06434792
Status:
RECRUITING
Last Update Posted:
2024-05-30
First Post:
2023-09-18
Brief Title:
Study to Evaluate Efficacy and Safety of Bronpass Tab in Patients With Chronic Obstructive Pulmonary Disease
Sponsor:
Hanlim Pharm Co Ltd
Organization:
Hanlim Pharm Co Ltd
Study Overview
Official Title:
A Multicenter Randomized Double-blind Placebo-controlled Parallel-group Dose-response Phase 2 Clinical Trial to Compare the Efficacy and Safety of Bronpass Tab Versus Placebo in Patients With Stable COPD
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical trial is a multicenter randomized double-blind placebo-controlled parallel-group dose-response phase 2 clinical trial study to evaluate the efficacy and safety of Bronpass Tab in 96 patients with chronic obstructive pulmonary disease
Detailed Description:
This study is to prove that Bronpass Tab is superior in clinical efficacy and safety in improving COPD symptoms compared to placebo for 12 weeks in patients suffering from chronic obstructive pulmonary disease
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None